Puma Posts Lower Earnings After Sales Suffer Currency Headwind
By Pierre Bertrand Puma reported a decline in first-quarter earnings after sales were hit by unfavorable currency effects. The German sporting-goods company said it made 87.3 million euros ($93.9 mi
Analysts Have Lowered Expectations For Puma Biotechnology, Inc. (NASDAQ:PBYI) After Its Latest Results
Puma Biotechnology First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Puma Biotechnology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Puma Biotechnology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : The Puma Biotechnology (PBYI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.
HC Wainwright & Co. : The Puma Biotechnology (PBYI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $7 price target.
Puma Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 43.44% HC Wainwright & Co. → $7 Reiterates Buy → Buy 03/01/2024 43.44% HC Wainwright & Co. $8 →
Earnings Call Summary | Puma Biotechnology(PBYI.US) Q1 2024 Earnings Conference
The following is a summary of the Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript:Financial Performance:Puma Biotechnology reported a total revenue of $43.8 million for Q1 2024, which
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript
Puma Biotechnology (PBYI) Receives a Sell From Barclays
Buy Rating Affirmed for Puma Biotechnology Amid Strong Q1 Performance and Promising Outlook
Puma Biotechnology Inc (PBYI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts
Puma Biotechnology Q1 2024 Adj EPS $(0.05) Beats $(0.22) Estimate, Sales $43.800M Beat $41.050M Estimate
Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.22) by 77.27 percent. This is a 155.56 percent decrease over earnings o
Press Release: Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology Reports First Quarter Financial Results LOS ANGELES--(BUSINESS WIRE)--May 02, 2024-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial resu
Puma Biotechnology 1Q Loss $4.8M >PBYI
Puma Biotechnology 1Q Loss $4.8M >PBYI
Puma Biotechnology Q1 2024 Earnings Preview
Puma Expected to See a Weak Start to the Year -- Market Talk
1049 GMT - Puma could see a soft performance for the first three months of the year, but it should achieve some improvement throughout the year, Warburg analyst Joerg Philipp Frey writes in a research
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial
No Data